Online inquiry

IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2404MR)

This product GTTS-WQ2404MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&EPCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_000733.4; NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 4072
UniProt ID P07766; P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2404MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11333MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ12189MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ8861MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ9679MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ11073MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ1099MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ5700MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ14286MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG7155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW